<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>World Pharma Today</title>
	<atom:link href="https://www.worldpharmatoday.com/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.worldpharmatoday.com</link>
	<description>Magazine for the C-level Pharma Executives</description>
	<lastBuildDate>Sat, 14 Nov 2026 07:11:16 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.4</generator>

<image>
	<url>https://www.worldpharmatoday.com/wp-content/uploads/2025/12/cropped-World-Pharma-Today-fevicon-32x32.jpg</url>
	<title>World Pharma Today</title>
	<link>https://www.worldpharmatoday.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Insulated Pallet Protection in Temperature-Sensitive Pharmaceutical Shipping</title>
		<link>https://www.worldpharmatoday.com/news/insulated-pallet-protection-in-temperature-sensitive-pharmaceutical-shipping/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Sat, 14 Nov 2026 07:11:16 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/insulated-pallet-protection-in-temperature-sensitive-pharmaceutical-shipping/</guid>

					<description><![CDATA[<p>In the pharmaceutical industry, products frequently require very specific temperatures to maintain quality and/or specific functions. Shipments are prone to risks as a result of inclement weather, loading time delays, and long transfers. So, it is important to plan and protect them. The effect of temperature changes outside the container is decreased by effectively providing [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/insulated-pallet-protection-in-temperature-sensitive-pharmaceutical-shipping/">Insulated Pallet Protection in Temperature-Sensitive Pharmaceutical Shipping</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Litmys and PharmaACE Establish Strategic Partnership for Market Projections</title>
		<link>https://www.worldpharmatoday.com/news/litmys-and-pharmaace-establish-strategic-partnership-for-market-projections/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Thu, 12 Nov 2026 12:57:56 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[IT & Data Management]]></category>
		<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/litmys-and-pharmaace-establish-strategic-partnership-for-market-projections/</guid>

					<description><![CDATA[<p>Life sciences consulting firms Litmys and PharmaACE have officially announced a strategic collaboration designed to deliver specialised decision-making and commercial forecasting solutions to the biotechnology and pharmaceutical sectors. This newly formed partnership specifically integrates real-world product adoption analytics with sophisticated commercial modelling. The core objective is to support companies in making informed choices regarding clinical [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/litmys-and-pharmaace-establish-strategic-partnership-for-market-projections/">Litmys and PharmaACE Establish Strategic Partnership for Market Projections</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Blackstone Provides Up to $1.5 Billion for Pfizer&#8217;s Obesity Drug Candidate</title>
		<link>https://www.worldpharmatoday.com/news/blackstone-provides-up-to-1-5-billion-for-pfizers-obesity-drug-candidate/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Thu, 12 Nov 2026 12:51:59 +0000</pubDate>
				<category><![CDATA[Drug Research]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Pfizer]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/blackstone-provides-up-to-1-5-billion-for-pfizers-obesity-drug-candidate/</guid>

					<description><![CDATA[<p>Private equity firm Blackstone Life Sciences has agreed to supply Pfizer with up to $1.5 billion in funding for the latter’s once-monthly candidate berobenatide. This capital infusion will directly support the ambitious GLP-1 drug development strategy for berobenatide, which is intended to offer patients less frequent injections compared to the current generation of once-weekly therapies [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/blackstone-provides-up-to-1-5-billion-for-pfizers-obesity-drug-candidate/">Blackstone Provides Up to $1.5 Billion for Pfizer’s Obesity Drug Candidate</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>How Biopharmaceutical Research Is Shaping the Future of Cancer Treatment</title>
		<link>https://www.worldpharmatoday.com/news/how-biopharmaceutical-research-is-shaping-the-future-of-cancer-treatment/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Thu, 12 Nov 2026 10:52:48 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/how-biopharmaceutical-research-is-shaping-the-future-of-cancer-treatment/</guid>

					<description><![CDATA[<p>Cancer is no longer viewed solely as a clinical condition to be treated using standard methods of cancer therapy. Ongoing research into cancer biology and its diverse molecular characteristics is supporting the investigation of emerging therapeutic strategies and clinical trials of investigational cancer treatments. These approaches are increasingly designed to target specific molecular changes and [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/how-biopharmaceutical-research-is-shaping-the-future-of-cancer-treatment/">How Biopharmaceutical Research Is Shaping the Future of Cancer Treatment</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Phase III CNS Protocol Optimization: Mitigating the Financial and Regulatory Risks of Multi-Site Imaging Scans</title>
		<link>https://www.worldpharmatoday.com/clinical-trails/phase-iii-cns-protocol-optimization-mitigating-the-financial-and-regulatory-risks-of-multi-site-imaging-scans/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Thu, 12 Nov 2026 07:49:36 +0000</pubDate>
				<category><![CDATA[Clinical Trials]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/phase-iii-cns-protocol-optimization-mitigating-the-financial-and-regulatory-risks-of-multi-site-imaging-scans/</guid>

					<description><![CDATA[<p>A scan can meet a site&#8217;s routine clinical standards and still leave a trial team with an unusable assessment. Across a global imaging network, that gap creates expenses that don&#8217;t sit neatly within the imaging budget: repeat visits, reconciliation work, and unresolved questions approaching database lock. Phase III CNS Protocol Optimization brings those operational exposures [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/clinical-trails/phase-iii-cns-protocol-optimization-mitigating-the-financial-and-regulatory-risks-of-multi-site-imaging-scans/">Phase III CNS Protocol Optimization: Mitigating the Financial and Regulatory Risks of Multi-Site Imaging Scans</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>OneSource Receives USFDA EIR with VAI Classification, Marking Completion of Inspection Process at its Sterile Product Division (SPD) Facility in Bengaluru</title>
		<link>https://www.worldpharmatoday.com/press-releases/onesource-receives-usfda-eir-with-vai-classification-marking-completion-of-inspection-process-at-its-sterile-product-division-spd-facility-in-bengaluru/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Thu, 12 Nov 2026 06:52:01 +0000</pubDate>
				<category><![CDATA[Press Releases]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/onesource-receives-usfda-eir-with-vai-classification-marking-completion-of-inspection-process-at-its-sterile-product-division-spd-facility-in-bengaluru/</guid>

					<description><![CDATA[<p>OneSource Specialty Pharma Limited announced that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its Sterile Product Division (SPD) facility in Bengaluru, with a &#8216;Voluntary Action Indicated&#8217; (VAI) classification. The report follows an inspection of the facility conducted from June 22 to June 30, 2026. Commenting [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/press-releases/onesource-receives-usfda-eir-with-vai-classification-marking-completion-of-inspection-process-at-its-sterile-product-division-spd-facility-in-bengaluru/">OneSource Receives USFDA EIR with VAI Classification, Marking Completion of Inspection Process at its Sterile Product Division (SPD) Facility in Bengaluru</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Thermo Fisher Scientific Offers Free Samples of Invitrogen Antibodies for Research Laboratories</title>
		<link>https://www.worldpharmatoday.com/press-releases/thermo-fisher-scientific-offers-free-samples-of-invitrogen-antibodies-for-research-laboratories/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Tue, 10 Nov 2026 13:29:55 +0000</pubDate>
				<category><![CDATA[Press Releases]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/thermo-fisher-scientific-offers-free-samples-of-invitrogen-antibodies-for-research-laboratories/</guid>

					<description><![CDATA[<p>Antibody performance is an important consideration in research workflows, where specificity, consistency and reliability can influence experimental results. Evaluating antibodies under actual laboratory conditions can help researchers assess their suitability before making a purchase. Thermo Fisher Scientific is offering researchers the opportunity to request free samples of selected Invitrogen™ antibodies to test their performance in [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/press-releases/thermo-fisher-scientific-offers-free-samples-of-invitrogen-antibodies-for-research-laboratories/">Thermo Fisher Scientific Offers Free Samples of Invitrogen Antibodies for Research Laboratories</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>What Pharmaceutical Professionals Should Know About AI Scribes</title>
		<link>https://www.worldpharmatoday.com/news/what-pharmaceutical-professionals-should-know-about-ai-scribes/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Tue, 10 Nov 2026 13:21:56 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/what-pharmaceutical-professionals-should-know-about-ai-scribes/</guid>

					<description><![CDATA[<p>A clinic pharmacist ends the day with twenty unsigned notes, and software she never checked wrote the first drafts. That scene is now common as ambient tools spread through clinics, pharmacies, and research sites. Federal privacy rules are tightening too. A proposed HIPAA Security Rule update raises the bar for how electronic patient data is [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/what-pharmaceutical-professionals-should-know-about-ai-scribes/">What Pharmaceutical Professionals Should Know About AI Scribes</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Biotech Succession Planning Strengthening Leadership Continuity During Growth</title>
		<link>https://www.worldpharmatoday.com/business-industry/biotech-succession-planning-strengthening-leadership-continuity-during-growth/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Tue, 10 Nov 2026 09:19:57 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/biotech-succession-planning-strengthening-leadership-continuity-during-growth/</guid>

					<description><![CDATA[<p>The identification of high-potential talent is the foundational step in building a sustainable leadership pipeline within the pharmaceutical industry. In an environment where specialized scientific knowledge is the primary driver of value, identifying individuals who possess both technical expertise and leadership potential is a complex but essential task. Successful biotech succession planning begins with a [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/business-industry/biotech-succession-planning-strengthening-leadership-continuity-during-growth/">Biotech Succession Planning Strengthening Leadership Continuity During Growth</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Cross-Functional Executive Alignment Improving Biotech Business Execution</title>
		<link>https://www.worldpharmatoday.com/business-industry/cross-functional-executive-alignment-improving-biotech-business-execution/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Tue, 10 Nov 2026 07:47:03 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/cross-functional-executive-alignment-improving-biotech-business-execution/</guid>

					<description><![CDATA[<p>Establishing a synchronized leadership structure serves as the cornerstone of operational success within the modern pharmaceutical sector. As companies move away from traditional silos, the integration of scientific expertise with commercial acumen becomes a mandatory requirement for managing the complex journey from laboratory discovery to patient access. This synthesis of perspectives ensures that every strategic [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/business-industry/cross-functional-executive-alignment-improving-biotech-business-execution/">Cross-Functional Executive Alignment Improving Biotech Business Execution</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
	</channel>
</rss>
